A Study of Avastin (Bevacizumab) and Oxaliplatin Plus Xeloda (Capecitabine) in Patients With Advanced Colorectal Cancer.

Phase II Study of the Combination of Bevacizumab (rhuMab VEGF) and Oxaliplatin Plus Capecitabine (XELOX) in Patients With Advanced Colorectal Cancer

This study will assess the efficacy and safety of treatment with the combination Avastin (bevacizumab) 5mg/kg iv every 2 weeks, Xeloda (capecitabine) 1000 mg po b.i.d. on Days 1-14 of every 28-day cycle and oxaliplatin 40mg/m2 iv weekly in patients with inoperable locally advanced or metastatic colorectal cancer. The anticipated time on study treatment is until disease progression.

Inclusion Criteria:

• Adult patients >=18 years of age
• Locally advanced or metastatic colorectal cancer
• No previous treatment with chemotherapy for metastatic disease
• Measurable and/or evaluable lesions

Exclusion Criteria:

• Radiotherapy within 4 weeks before study
• Untreated brain metastases or primary brain tumors
• Chronic, daily treatment with high-dose aspirin (>325mg/day)
• Co-existing malignancies, or malignancies diagnosed within the last 5 years, with the exception of basal and squamous cell cancer, or cervical cancer in situ